孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗哮喘的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Montelukast Sodium combined with Salmeterol and Fluticasone Propionate Powders for Inhalation in treatment of asthma.Methods A total of 100 patients with asthma who were admitted to the department of respiratory medicine of our hospital from July 2014 to September 2016 were selected as subjects.They were divided into two groups according to the random number table method,50 cases in eacgh group.The patients in the control group were given conventional treatment with Salmeterol and Fluticasone Propionate Powders for Inhalation,while the patients in the analysis group were added to the treatment of Montelukast Sodium on the basis of the control group.The lung function indicators(lung capacity,exhalation volume,maximum expiratory flow rate),the therapeutic effect and disappearance time of various clinical symptoms of the two groups were compared.Results Before treatment,there was no significant difference in lung function indicators between the two groups (P＞0.05).After treatment,the levels of lung function indicators in the analysis group were significantly higher than those in the control group,and the differences were statistically significant(P＜0.05).The total effective rate of treatment in the analysis group was 96.00%(48/50),which was significantly higher than 68.00%(34/50)in the control group,and the difference was statistically significant(P＜0.05).The disappearance time of cough and asthma in the analysis group were significantly shorter than those in the control group,and the differences were statistically significant(P＜0.05).Conclusion Montelukast Sodium combined with Salmeterol and Fluticasone Propionate Powders for Inhalation is more effective in treatment of asthma.It can effectively shorten the disappearance time of symptoms and improve lung function.It has clinical application value.

Key words： Montelukast Sodium Salmeterol and Fluticasone Propionate Powders for Inhalation Asthma Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MO Jian-rong
	HUANG Nian-hua
	LI Xiao-hua

Cite this article:

MO Jian-rong,HUANG Nian-hua,LI Xiao-hua. Clinical efficacy of Montelukast Sodium combined with Salmeterol and Fluticasone Propionate Powders for Inhalation in treatment of asthma[J]. 中国当代医药, 2018, 25(14): 132-134转138.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I14/132

[1]	解颖，陈建丽，徐超，等.孟鲁司特联合舒利迭治疗哮喘的临床疗效及对Th17、Treg细胞平衡和IL-4、IFN-γ表达的影响[J].中国生化药物杂志，2015，7（5）：127-129.
[2]	向繁，印季，唐云良.孟鲁司特联合舒利迭治疗哮喘的临床疗效及对炎症因子表达的影响[J].当代医学，2017，23（23）：130-132.
[3]	陈远山.孟鲁司特联合舒利迭治疗哮喘的临床疗效探讨[J].临床研究，2016，24（2）：105.
[4]	周世林.两药联合治疗小儿咳嗽变异性哮喘的疗效观察[J].临床肺科杂志，2015，8（1）：162-163.
[5]	庄明凤，马敬斌，殷汝昌，等.孟鲁司特咀嚼片对咳嗽变异性哮喘肺功能的影响[J].临床肺科杂志，2017，22（1）：89-92.
[6]	刘宇智，金宁，王海斌.孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的疗效分析[J].临床肺科杂志，2017，22（7）：1293-1296.
[7]	王雪玉，陈雅祺，钟四秀.孟鲁司特钠预防小儿哮喘急性发作的效果研究[J].临床肺科杂志，2017，22（5）：887-889.
[8]	石晓岚，刘翠翠，赵龙，等.孟鲁司特钠治疗儿童哮喘的临床症状和肺功能评估[J].临床肺科杂志，2016，21（6）：1034-1037.
[9]	陈颖.舒利迭联合扎鲁司特治疗儿童支气管哮喘的疗效及对肺功能的影响[J].临床肺科杂志，2016，6（3）：558-559.
[10]	陈凡，焦琳，吴莎，等.孟鲁司特联合抗生素治疗支气管扩张症的临床观察[J].临床肺科杂志，2015，17（9）：1703-1706.
[11]	孙安凤.舒利迭联合孟鲁司特钠对哮喘的临床疗效观察[J].吉林医学，2015，36（7）：1386-1387.
[12]	冯志红，聂秀红.孟鲁司特钠治疗咳嗽变异性哮喘的疗效及诱导痰中炎性介质的影响[J].临床肺科杂志，2015，11（11）：2011-2014.
[13]	黎剑泉，徐小琳，邹云新.孟鲁司特钠联合舒利迭治疗支气管哮喘的临床分析[J].中国医学创新，2015，12（14）：148-149.
[14]	顾慧玲.老年支气管哮喘患者FeNO与肺功能的相关性[J].临床肺科杂志，2015，9（7）：1293-1295.
[15]	李晓宁，周超，王玺.孟鲁司特钠联合舒利迭治疗CVA的效果及机制研究[J].西南国防医药，2017，27（6）：604-606.